John is currently Vice President, Global Health and Value for Pfizer’s Essential Health business unit, which has worldwide sales of more than $20B from a portfolio of over 700 molecules including biosimilars, sterile injectables and solid oral dosage forms. The portfolio is the result of Pfizer’s research and development as well as from the acquisitions of Warner Lambert, Pharmacia and Upjohn, Wyeth and most recently Hospira. Pfizer is the world’s leading biosimilars company based on audited sales and its portfolio of biosimilar molecules is for the treatment of inflammation, oncology and supportive care.

Pfizer’s Global Health and Value team covers the functions of Pricing, Access, Reimbursement, Health Economics, Outcomes Research and Real World Data.  John has been with Pfizer for over 18 years in multiple roles of increasing responsibilities, the last three years in his current role.  He has presented at several conferences on the topic of pricing, access and health economics.